Myostatin levels were significantly elevated in myocardial infarction and atherosclerosis patients compared to healthy individuals, suggesting it as a potential biomarker.
Are serum myostatin levels and associated biochemical parameters altered in patients with myocardial infarction and atherosclerosis compared to healthy controls?
Serum myostatin is significantly elevated in patients with myocardial infarction and atherosclerosis, suggesting its potential utility as a supplementary biomarker for cardiovascular disease assessment.
Absolute Event Rate: 0% vs 0%
In order to assess the significance of myostatin protein with some biochemical parameters in the blood serum of myocardial infarction and atherosclerosis patients. The study included 60 samples of heart patients (30 samples of myocardial infarction patients and 30 samples of patients with atherosclerosis) whose ages ranged from 35 to 65 years, in addition to 30 samples of healthy people of the same age group. Results revealed a marked rise in the level of myostatin protein in the myocardial infarction and atherosclerosis patients in comparison to healthy group, and rise in troponin protein in myocardial infarction patients. According to the findings, total cholesterol, triglycerides, low-density lipoproteins, and very-low-density lipoproteins were all significantly higher in the two patients groups than in healthy group, whereas high-density lipoprotein levels were significantly lower in both patients groups. The results indicated that calcium level had significantly decreased in myocardial infarction patients, but no change in phosphate level between groups. The findings revealed a significantly lower of glutathione and a significantly higher of malondialdehyde in the two patients groups as compared to the healthy group. In conclusion, the obtained data were directly aligned with the study hypothesis, showing significant elevation of myostatin and associated biochemical changes relevant to the pathophysiology of myocardial infarction and atherosclerosis, thus supporting the study objective. Results suggest myostatin as a potential supplementary biomarker and highlight useful biochemical alterations for patient assessment; however, lack of established diagnostic cut-offs, limited routine availability of myostatin testing, and small sample size may limit immediate clinical application.
Dhahir et al. (Tue,) reported a other. Myostatin levels were significantly elevated in myocardial infarction and atherosclerosis patients compared to healthy individuals, suggesting it as a potential biomarker.